전체메뉴
검색
Article Search

JMB Journal of Microbiolog and Biotechnology

QR Code QR Code

Research article

References

  1. Bright, R. A., D. K. Shay, B. Shu, N. J. Cox, and A. I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
    Pubmed CrossRef
  2. Cassetti, M. C., R. Couch, J. Wood, and Y. Pervikov. 2005. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004. Vaccine 23: 1529-1533.
    Pubmed CrossRef
  3. CDC. 2009. Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. Morb. Mortal. Wkly. Rep. 58.
    Pubmed
  4. Choi, H. J., J. H. Song, K. S. Park, and D. H. Kwon. 2009. Inhibitory effects of quercetin 3-rhamnoside on influenza A virus replication. Eur. J. Pharm. Sci. 37: 329-333.
    Pubmed CrossRef
  5. Chomczynski, P. and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal. Biochem. 162: 156-159.
    CrossRef
  6. Condit, R. C. 2006. Fields virology, pp. 25-57. In D. M. Knipe and P. M. Howley (eds.). Principles of Virology, 5th Ed. Lippincott Williams and Wilkins, Philadelphia.
  7. Couch, R. B. and G. G. Jackson. 1976. Antiviral agents in influenza - summary of Influenza Workshop VIII. J. Infect. Dis. 134: 516-527.
    Pubmed CrossRef
  8. De Clercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30: 115-133.
    Pubmed CrossRef
  9. Furuta, Y., K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, et al. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49:981-986.
    Pubmed PMC CrossRef
  10. Garten, R. J., C. T. Davis, C. A. Russell, B. Shu, S. Lindstrom, A. Balish, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
    Pubmed PMC CrossRef
  11. Glezen, W. P. 1996. Emerging infections: Pandemic influenza. Epidemiol. Rev. 18: 64-76.
    Pubmed CrossRef
  12. Hampson, A. W. 2002. Influenza virus antigens and ‘antigenic drift’, pp. 49-85. In C. W. Potter (ed.). Perspectives in Medical Virology, Vol. 7. Elsevier.
  13. Hui, E. K. and D. P. Nayak. 2001. Role of ATP in influenza virus budding. Virology 290: 329-341.
    Pubmed CrossRef
  14. Irvine, J. D., L. Takahashi, K. Lockhart, J. Cheong, J. W. Tolan, H. E. Selick, and J. R. Grove. 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci. 88: 28-33.
    Pubmed CrossRef
  15. Jackson, D. C. and L. E. Brown. 1991. A synthetic peptide of influenza virus hemagglutinin as a model antigen and immunogen. Pept. Res. 4: 114-124.
    Pubmed
  16. Kawaoka, Y. 2006. Influenza Virology: Current Topics. Caister Academic Press.
  17. Kelly, H. and K. Grant. 2009. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: Surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro. Surveill. 14.
  18. Kiso, M., K. Takahashi, Y. Sakai-Tagawa, K. Shinya, S. Sakabe, Q. M. Le, et al. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. USA 107:882-887.
    Pubmed PMC CrossRef
  19. Murris-Espin, M., A. Didier, S. Mezghani, L. Lacassagne, and P. Leophonte. 1999. Influenza and asthma. Rev. Mal. Res. 16:9-15.
    Pubmed
  20. Noah, J. W., W. Severson, D. L. Noah, L. Rasmussen, E. L. White, and C. B. Jonsson. 2007. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res. 73: 50-59.
    Pubmed CrossRef
  21. Numazaki, Y., T. Oshima, A. Ohmi, A. Tanaka, Y. Oizumi, S. Komatsu, et al. 1987. A microplate method for isolation of viruses from infants and children with acute respiratory infections. Microbiol. Immunol. 31: 1085-1095.
    Pubmed
  22. Palese, S. M. 2007. Orthomyxoviridae: The viruses and their replication, pp. 1647-1689. In K. DM and H. PM (eds.). Fields Virology, 5th Ed. Lippincott Williams &Wilkins, Philadelphia.
  23. Poland, G. A., R. M. Jacobson, and P. V. Targonski. 2007. Avian and pandemic influenza: An overview. Vaccine 25:3057-3061.
    Pubmed CrossRef
  24. Renaud, C., J. Kuypers, and J. A. Englund. 2011. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J. Clin. Virol. 52: 70-78.
    Pubmed CrossRef
  25. WHO. 2009. Summary report of a high-level consultation: New influenza A (H1N1). World Health Organization, Geneva.

Related articles in JMB

More Related Articles

Article

Research article

J. Microbiol. Biotechnol. 2013; 23(1): 125-130

Published online January 28, 2013 https://doi.org/10.4014/jmb.1210.10074

Copyright © The Korean Society for Microbiology and Biotechnology.

Antiviral Activity of the Plant Extracts from Thuja orientalis, Aster spathulifolius, and Pinus thunbergii Against Influenza Virus A/PR/8/34

Ji-Na Won 1, 2, Seo-Yong Lee 1, Dae-Sub Song 1, 2 and Haryoung Poo 1, 2*

1Viral Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon, Korea, 2University of Science and Technology, Daejeon, Korea

Received: October 29, 2012; Accepted: November 20, 2012

Abstract

Influenza viruses cause significant morbidity and mortality
in humans through epidemics or pandemics. Currently,
two classes of anti-influenza virus drugs, M2 ion-channel
inhibitors (amantadin and rimantadine) and neuraminidase
inhibitors (oseltamivir and zanamivir), have been used
for the treatment of the influenza virus infection. Since
the resistance to these drugs has been reported, the
development of a new antiviral agent is necessary. In this
study, we examined the antiviral efficacy of the plant
extracts against the influenza A/PR/8/34 infection. In
vitro, the antiviral activities of the plant extracts were
investigated using the cell-based screening. Three plant
extracts, Thuja orientalis, Aster spathulifolius, and Pinus
thunbergii, were shown to induce a high cell viability rate
after the infection with the influenza A/PR/8/34 virus. The
antiviral activity of the plant extracts also increased as a
function of the concentration of the extracts and these
extracts significantly reduced the visible cytopathic effect
caused by virus infections. Furthermore, the treatment
with T. orientalis was shown to have a stronger inhibitory
effect than that with A. spathulifolius or P. thunbergii. These
results may suggest that T. orientalis has anti-influenza
A/PR/8/34 activity.

Keywords: plant extract, Influenza A virus, antiviral activity, cytopathic effect

References

  1. Bright, R. A., D. K. Shay, B. Shu, N. J. Cox, and A. I. Klimov. 2006. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295: 891-894.
    Pubmed CrossRef
  2. Cassetti, M. C., R. Couch, J. Wood, and Y. Pervikov. 2005. Report of meeting on the development of influenza vaccines with broad spectrum and long-lasting immune responses, World Health Organization, Geneva, Switzerland, 26-27 February 2004. Vaccine 23: 1529-1533.
    Pubmed CrossRef
  3. CDC. 2009. Effectiveness of 2008-09 trivalent influenza vaccine against 2009 pandemic influenza A (H1N1) - United States, May-June 2009. Morb. Mortal. Wkly. Rep. 58.
    Pubmed
  4. Choi, H. J., J. H. Song, K. S. Park, and D. H. Kwon. 2009. Inhibitory effects of quercetin 3-rhamnoside on influenza A virus replication. Eur. J. Pharm. Sci. 37: 329-333.
    Pubmed CrossRef
  5. Chomczynski, P. and N. Sacchi. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenolchloroform extraction. Anal. Biochem. 162: 156-159.
    CrossRef
  6. Condit, R. C. 2006. Fields virology, pp. 25-57. In D. M. Knipe and P. M. Howley (eds.). Principles of Virology, 5th Ed. Lippincott Williams and Wilkins, Philadelphia.
  7. Couch, R. B. and G. G. Jackson. 1976. Antiviral agents in influenza - summary of Influenza Workshop VIII. J. Infect. Dis. 134: 516-527.
    Pubmed CrossRef
  8. De Clercq, E. 2004. Antiviral drugs in current clinical use. J. Clin. Virol. 30: 115-133.
    Pubmed CrossRef
  9. Furuta, Y., K. Takahashi, M. Kuno-Maekawa, H. Sangawa, S. Uehara, K. Kozaki, et al. 2005. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49:981-986.
    Pubmed KoreaMed CrossRef
  10. Garten, R. J., C. T. Davis, C. A. Russell, B. Shu, S. Lindstrom, A. Balish, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science 325: 197-201.
    Pubmed KoreaMed CrossRef
  11. Glezen, W. P. 1996. Emerging infections: Pandemic influenza. Epidemiol. Rev. 18: 64-76.
    Pubmed CrossRef
  12. Hampson, A. W. 2002. Influenza virus antigens and ‘antigenic drift’, pp. 49-85. In C. W. Potter (ed.). Perspectives in Medical Virology, Vol. 7. Elsevier.
  13. Hui, E. K. and D. P. Nayak. 2001. Role of ATP in influenza virus budding. Virology 290: 329-341.
    Pubmed CrossRef
  14. Irvine, J. D., L. Takahashi, K. Lockhart, J. Cheong, J. W. Tolan, H. E. Selick, and J. R. Grove. 1999. MDCK (Madin-Darby canine kidney) cells: A tool for membrane permeability screening. J. Pharm. Sci. 88: 28-33.
    Pubmed CrossRef
  15. Jackson, D. C. and L. E. Brown. 1991. A synthetic peptide of influenza virus hemagglutinin as a model antigen and immunogen. Pept. Res. 4: 114-124.
    Pubmed
  16. Kawaoka, Y. 2006. Influenza Virology: Current Topics. Caister Academic Press.
  17. Kelly, H. and K. Grant. 2009. Interim analysis of pandemic influenza (H1N1) 2009 in Australia: Surveillance trends, age of infection and effectiveness of seasonal vaccination. Euro. Surveill. 14.
  18. Kiso, M., K. Takahashi, Y. Sakai-Tagawa, K. Shinya, S. Sakabe, Q. M. Le, et al. 2010. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc. Natl. Acad. Sci. USA 107:882-887.
    Pubmed KoreaMed CrossRef
  19. Murris-Espin, M., A. Didier, S. Mezghani, L. Lacassagne, and P. Leophonte. 1999. Influenza and asthma. Rev. Mal. Res. 16:9-15.
    Pubmed
  20. Noah, J. W., W. Severson, D. L. Noah, L. Rasmussen, E. L. White, and C. B. Jonsson. 2007. A cell-based luminescence assay is effective for high-throughput screening of potential influenza antivirals. Antiviral Res. 73: 50-59.
    Pubmed CrossRef
  21. Numazaki, Y., T. Oshima, A. Ohmi, A. Tanaka, Y. Oizumi, S. Komatsu, et al. 1987. A microplate method for isolation of viruses from infants and children with acute respiratory infections. Microbiol. Immunol. 31: 1085-1095.
    Pubmed
  22. Palese, S. M. 2007. Orthomyxoviridae: The viruses and their replication, pp. 1647-1689. In K. DM and H. PM (eds.). Fields Virology, 5th Ed. Lippincott Williams &Wilkins, Philadelphia.
  23. Poland, G. A., R. M. Jacobson, and P. V. Targonski. 2007. Avian and pandemic influenza: An overview. Vaccine 25:3057-3061.
    Pubmed CrossRef
  24. Renaud, C., J. Kuypers, and J. A. Englund. 2011. Emerging oseltamivir resistance in seasonal and pandemic influenza A/H1N1. J. Clin. Virol. 52: 70-78.
    Pubmed CrossRef
  25. WHO. 2009. Summary report of a high-level consultation: New influenza A (H1N1). World Health Organization, Geneva.